Skip to main content
Make a Gift

Follow us at our Bluesky account @unc-brc.bsky.social

The UNC Blood Research Center (BRC) was established to promote interdisciplinary research in non-malignant blood disorders across UNC. It will seek to advance the work in the following specific areas.

Thrombosis

One in four of the US population will succumb to a terminal thrombotic event, such as: myocardial infarction, stroke, or venous thromboembolism.

Basic science discoveries have paved the way towards better prophylactic and therapeutic approaches to thrombosis. However, a better understanding of the mechanisms underlying thrombosis and prevention without any risk of bleeding remains an unmet need. The BRC seeks to investigate potential approaches to both aims.

Bleeding Disorders

UNC is a world leader in hemophilia, from the development and administration of the first coagulation factor VIII concentrate to the role of the Chapel Hill dog colonies of the Francis Owen Blood Research Center in the pre-clinical testing of protein and gene therapies. The BRC aims to address the broad challenges that remain in numerous other inherited and acquired bleeding disorders.

Sickle Cell Disease

Sickle cell disease affects approximately 100,000 Americans but accounts for an estimated 300,000 births worldwide every year, primarily in sub-Saharan Africa and the Indian sub-continent.

Compared to many other areas of medicine, the development of impactful therapies in sickle cell disease remains inadequate. We will continue to expand our research efforts to this under-served patient population into the future.

Events/Seminars

Tuesday 9:00 am

Tuesday BRC Lab Meeting

Tuesday 9:00 am

Tuesday BRC Lab Meeting

Tuesday 9:00 am

Tuesday BRC Lab Meeting: Trainee Short Talks (clinical)

Tuesday 9:00 am

Tuesday BRC Lab Meeting

View All Events

News

Recent Posts

News from the Blood Research Center

More posts
Dr. Nigel Key

3 weeks ago

Key Lab publishes study describing rapid and sensitive assay for hyperfibrinolysis in plasma

Key Lab publishes study describing rapid and sensitive assay for hyperfibrinolysis in plasma. In collaboration with colleagues in the UK who first described a form of severe post-partum hemorrhage (PPH) characterized by marked hyperfibrinolysis, a novel rapid assay for fibrinolytic activation in plasma developed in the lab (the Fibrinolytic Activation Screening Test or ‘FAST’ assay) reliably distinguished Acute Obstetric …